» Articles » PMID: 24650449

Chronic Stress Accelerates Pancreatic Cancer Growth and Invasion: a Critical Role for Beta-adrenergic Signaling in the Pancreatic Microenvironment

Overview
Publisher Elsevier
Date 2014 Mar 22
PMID 24650449
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer cells intimately interact with a complex microenvironment that influences pancreatic cancer progression. The pancreas is innervated by fibers of the sympathetic nervous system (SNS) and pancreatic cancer cells have receptors for SNS neurotransmitters which suggests that pancreatic cancer may be sensitive to neural signaling. In vitro and non-orthotopic in vivo studies showed that neural signaling modulates tumour cell behavior. However the effect of SNS signaling on tumor progression within the pancreatic microenvironment has not previously been investigated. To address this, we used in vivo optical imaging to non-invasively track growth and dissemination of primary pancreatic cancer using an orthotopic mouse model that replicates the complex interaction between pancreatic tumor cells and their microenvironment. Stress-induced neural activation increased primary tumor growth and tumor cell dissemination to normal adjacent pancreas. These effects were associated with increased expression of invasion genes by tumor cells and pancreatic stromal cells. Pharmacological activation of β-adrenergic signaling induced similar effects to chronic stress, and pharmacological β-blockade reversed the effects of chronic stress on pancreatic cancer progression. These findings indicate that neural β-adrenergic signaling regulates pancreatic cancer progression and suggest β-blockade as a novel strategy to complement existing therapies for pancreatic cancer.

Citing Articles

Molecular Characterization of Cancer Preventive and Therapeutic Potential of Three Antistress Compounds, Triethylene Glycol, Withanone, and Withaferin A.

Zhang H, Kim H, Yuan T, Zhang Z, Kaul S, Wadhwa R Int J Mol Sci. 2025; 26(2.

PMID: 39859209 PMC: 11764651. DOI: 10.3390/ijms26020493.


Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment.

Huang Q, Hu B, Zhang P, Yuan Y, Yue S, Chen X Mol Cancer. 2025; 24(1):24.

PMID: 39825376 PMC: 11740516. DOI: 10.1186/s12943-024-02219-0.


Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma.

Kluz N, Kraj L, Chmiel P, Przybylkowski A, Wyrwicz L, Stec R Cancers (Basel). 2024; 16(23).

PMID: 39682132 PMC: 11640600. DOI: 10.3390/cancers16233945.


Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer.

Sun X, Teper Y, Sinnet-Smith J, Sinnett-Smith J, Markarian M, Hines O Mol Cancer Res. 2024; 23(3):236-249.

PMID: 39642318 PMC: 11875952. DOI: 10.1158/1541-7786.MCR-24-0785.


Pancreatic Ductal Adenocarcinoma, β-blockers, and Antihistamines: A Clinical Trial Is Needed.

Baker J, Sloan E, Pfleger K, Pfleger K, McCormick P, Salmeron C Function (Oxf). 2024; 6(1).

PMID: 39547938 PMC: 11815576. DOI: 10.1093/function/zqae050.


References
1.
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S . The prevalence of psychological distress by cancer site. Psychooncology. 2001; 10(1):19-28. DOI: 10.1002/1099-1611(200101/02)10:1<19::aid-pon501>3.0.co;2-6. View

2.
Zhang D, Ma Q, Hu H, Zhang M . β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 2010; 10(1):19-29. DOI: 10.4161/cbt.10.1.11944. View

3.
Manni L, di Fausto V, Fiore M, Aloe L . Repeated restraint and nerve growth factor administration in male and female mice: effect on sympathetic and cardiovascular mediators of the stress response. Curr Neurovasc Res. 2008; 5(1):1-12. DOI: 10.2174/156720208783565654. View

4.
Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View

5.
Morizono K, Xie Y, Ringpis G, Johnson M, Nassanian H, Lee B . Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005; 11(3):346-52. DOI: 10.1038/nm1192. View